Loading
Drug Therapy, Combination / Adrenergic Beta-antagonists · Journal article
Journal of Medical Economics · June 8, 2026
Reinforces what was already believed, rather than introducing something new.
This model-based cost-effectiveness analysis from a Dutch societal perspective finds mavacamten plus beta-blocker/calcium channel blocker therapy is cost-effective versus monotherapy for symptomatic obstructive hypertrophic cardiomyopathy at a €50,000 per QALY threshold. The incremental cost-utility ratio of €15,961 per QALY gained falls well below accepted Dutch willingness-to-pay thresholds, with sensitivity analyses confirming the robustness of findings.
5-state Markov cost-effectiveness model. Model population reflected the EXPLORER-HCM trial intention-to-treat population (patients with symptomatic obstructive hypertrophic cardiomyopathy). Intervention: Mavacamten + beta-blocker/calcium channel blocker therapy (BB/CCB). Compared with: BB/CCB monotherapy. Netherlands.
Mavacamten + BB/CCB resulted in an incremental discounted gain of 3.09 QALYs and 3.17 LYs versus BB/CCB monotherapy Incremental discounted costs were €49,388 over a lifetime Incremental cost-utility ratio was €15,961 per QALY gained, cost-effective at €50,000 per QALY threshold
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
For Dutch clinicians treating symptomatic obstructive HCM, this analysis supports mavacamten plus background therapy as a cost-effective strategy that provides meaningful quality-adjusted life-year gains at an acceptable societal cost. The favorable incremental cost-utility ratio suggests the therapy represents good value despite higher acquisition costs, driven largely by reductions in informal care and healthcare utilization.
Model-based cost-effectiveness analysis demonstrates mavacamten meets accepted Dutch societal willingness-to-pay thresholds using established Markov modeling methods and published trial data.
As stated by the source record.
Quoted from the source exactly as published.
For Dutch clinicians treating symptomatic obstructive HCM, this analysis supports mavacamten plus background therapy as a cost-effective strategy that provides meaningful quality-adjusted life-year gains at an acceptable societal cost. The favorable incremental cost-utility ratio suggests the therapy represents good value despite higher acquisition costs, driven largely by reductions in informal care and healthcare utilization.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objectives. To explore the cost-effectiveness of mavacamten + beta-blocker/calcium channel blocker therapy (BB/CCB) versus BB/CCB monotherapy for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM).Materials and methods. A 5-state Markov model (New York Heart Association classes I-IV, death) that included treatment sequencing was developed. It used a Dutch societal perspective and lifetime horizon stratified into short-term (mavacamten + BB/CCB: 30 weeks; BB/CCB: 46 weeks) and long-term (i.e. post short-term) periods. The model population reflected the EXPLORER-HCM trial intention-to-treat population. Model parameters were aligned with 2016 Zorginstituut Nederland guidelines, including annual discount rates of 4.00% and 1.50% for costs and health outcomes. Costs (2022/2023 Euros), life-years (LYs) and quality-adjusted LYs (QALYs) per patient, incremental costs and LYs/QALYs, and incremental cost-utility ratios were estimated. Sensitivity and scenario analyses were conducted to evaluate the robustness of the results.Results. Treatment with mavacamten + BB/CCB resulted in an incremental discounted gain of 3.09 QALYs and 3.17 LYs versus the BB/CCB monotherapy strategy. Incremental discounted costs were €49,388 over a lifetime; the additional costs of mavacamten were driven by increased treatment acquisition costs but partly offset by savings in healthcare resource utilization and indirect costs, particularly informal care costs. Mavacamten + BB/CCB was cost-effective at a €50,000 per QALY threshold versus BB/CCB monotherapy at €15,961 per QALY gain. The deterministic and probabilistic sensitivity and scenario analyses supported the robustness of the model results.Conclusions. In the Netherlands, mavacamten + BB/CCB is a cost-effective treatment strategy for symptomatic obstructive HCM compared to BB/CCB monotherapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.